a proto-oncogenic transcription factor homologous to the v-ets erythroblastosis virus oncogene. The DNA binding activity of Ets1 is controlled by kinases and transcription factors. It contributes to the regulation of cellular differentiation in hematopoietic cells. Ets1 promotes invasive behavior in endothelial cells, vascular smooth muscle cells and epithelial cancer cells. Regulates the expression of MMP1, MMP3, MMP9 and uPA as well as of VEGF and VEGFR gene expression. Two alternatively spliced isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: DNA-binding; Motility/polarity/chemotaxis; Oncoprotein; Transcription factor
Molecular Function: histone acetyltransferase binding; protein binding; DNA binding; sequence-specific DNA binding; transcription factor binding; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; hypothalamus development; positive regulation of erythrocyte differentiation; positive regulation of transcription, DNA-dependent; cell motility involved in cell locomotion; PML body organization and biogenesis; female pregnancy; positive regulation of cell motility; angiogenesis involved in wound healing; regulation of angiogenesis; response to estradiol stimulus; negative regulation of cell cycle; regulation of apoptosis; response to antibiotic; negative regulation of cell proliferation; positive regulation of angiogenesis; response to mechanical stimulus; pituitary gland development; positive regulation of cell proliferation; response to hypoxia; positive regulation of transcription from RNA polymerase II promoter; immune response
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.